Abstract: The invention discloses use of a pharmaceutical composition for slow-release delivery of a bioactive agent, comprising mixing the bioactive agent with a partially hydrophobic chitosan solution at a low pH and delivering the hydrogel at a physiological pH to transform the hydrogel to a solid complex for releasing the bioactive agent. The partially hydrophobic chitosan is characterized by presence of alternating charges of protonated amine groups and hydrophobic side groups.

Abstract: The invention discloses a pharmaceutical composition of pH-sensitive liposome nanoparticles for lodging in a target tissue cell in situ of an animal subject, the nanoparticles comprising a proton-releasing photosensitive compound that releases protons upon photolysis, wherein the compound is in vesicles of the liposomes. A light or UV light is provided to induce the photosensitive compound to release the protons, thus the released protons causing the pH-sensitive liposome to decompose.

Abstract: The invention discloses a pharmaceutical composition of nanoparticles consisting of chitosan, a negatively charged substrate, and at least one bioactive agent that is encapsulated within cucurbiturils for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: The invention discloses a composition of nanoparticles composed of positively charged chitosan, one negatively charged substrate, and optionally a zero-charge compound or at least one tumor necrosis factor inhibitor for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one DNA, RNA or bioactive agent characterized with a positive surface charge and their enhanced efficiency for gene delivery and bioactive agent delivery.

Abstract: The invention discloses the nanoparticles composed of chitosan, poly-?-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Abstract: The invention discloses a pharmaceutical composition of multifunctional core-shell nanoparticles, each nanoparticle comprising: a core portion comprised of hydrophobic poly(D,L-lactic-co-glycolic acid) (PLGA) and a detection-enhancing substance, and a shell portion comprised of positively charged chitosan adapted to cause no aggregation of nanoparticles due to electrostatic repulsion between the positively charged nanoparticles. In one embodiment, the detection-enhancing substance includes SPIO, a quantum dot, a fluorescent quantum dot, a bubble, an air bubble, and the like.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for drug delivery.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: The invention discloses a pharmaceutical composition of liposome nanoparticles for lodging in a target tissue cell in situ of an animal subject, the nanoparticles comprising at least one thermal triggered phase-transition compound as a targeting drug delivery system for physical cancer therapy.

Abstract: The invention discloses a pharmaceutical composition of liposome nanoparticles for lodging in a target tissue cell in situ of an animal subject, the nanoparticles comprising at least one thermal triggered phase-transition compound as a targeting drug delivery system for physical cancer therapy.

Abstract: The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial permeability for oral drug delivery.

Abstract: The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network enabling improved loading the bioactive agent.

Abstract: The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial ermeability for oral drug delivery.

Abstract: The invention relates to a method for treating disorders or diseases of a tight junction comprising delivering a pharmaceutical composition of nanoparticles to the tight junction, wherein the nanoparticles consist of positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating said disorders or diseases of the tight junction of an animal subject.

Abstract: The invention relates to a pharmaceutical composition of nanoparticles, wherein the nanoparticles comprise positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating diabetes of an animal subject.

Abstract: The invention discloses nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein the bioactive agent may include mitofusin 1, mitofusin 2, and/or anti-diabetic compounds.